Literature DB >> 15289092

Biological agents with potential for misuse: a historical perspective and defensive measures.

Deepak K Bhalla1, David B Warheit.   

Abstract

Biological and chemical agents capable of producing serious illness or mortality have been used in biowarfare from ancient times. Use of these agents has progressed from crude forms in early and middle ages, when snakes and infected cadavers were used as weapons in battles, to sophisticated preparations for use during and after the second World War. Cults and terrorist organizations have attempted the use of biological agents with an aim to immobilize populations or cause serious harm. The reasons for interest in these agents by individuals and organizations include relative ease of acquisition, potential for causing mass casualty or panic, modest financing requirement, availability of technology, and relative ease of delivery. The Centers for Disease Control and Prevention has classified Critical Biological Agents into three major categories. This classification was based on several criteria, which include severity of impact on human health, potential for delivery in a weapon, capacity to cause panic and special needs for development, and stockpiling of medication. Agents that could cause the greatest harm following deliberate use were placed in category A. Category B included agents capable of producing serious harm and significant mortality but of lower magnitude than category A agents. Category C included emerging pathogens that could be developed for mass dispersion in future and their potential as a major health threat. A brief description of the category A bioagents is included and the pathophysiology of two particularly prominent agents, namely anthrax and smallpox, is discussed in detail. The potential danger from biological agents and their ever increasing threat to human populations have created a need for developing technologies for their early detection, for developing treatment strategies, and for refinement of procedures to ensure survival of affected individuals so as to attain the ultimate goal of eliminating the threat from intentional use of these agents. International treaties limiting development and proliferation of weapons and continuing development of defense strategies and safe guards against agents of concern are important elements of plans for eliminating this threat.

Entities:  

Mesh:

Year:  2004        PMID: 15289092     DOI: 10.1016/j.taap.2004.03.009

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

1.  5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity.

Authors:  Xuesen Fan; Xinying Zhang; Longhu Zhou; Kathy A Keith; Earl R Kern; Paul F Torrence
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

2.  Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.

Authors:  Brandon Feinen; Nikolai Petrovsky; Anita Verma; Tod J Merkel
Journal:  Clin Vaccine Immunol       Date:  2014-02-19

3.  Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Authors:  Richard Kennedy; V Shane Pankratz; Eric Swanson; David Watson; Hana Golding; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2009-06-17

4.  Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.

Authors:  Yves P Gauthier; Jean-Nicolas Tournier; Jean-Charles Paucod; Jean-Philippe Corre; Michèle Mock; Pierre L Goossens; Dominique R Vidal
Journal:  Infect Immun       Date:  2008-12-29       Impact factor: 3.441

5.  Single domain antibodies for the detection of ricin using silicon photonic microring resonator arrays.

Authors:  Winnie W Shia; Ryan C Bailey
Journal:  Anal Chem       Date:  2012-12-28       Impact factor: 6.986

6.  Learning virulent proteins from integrated query networks.

Authors:  Eithon Cadag; Peter Tarczy-Hornoch; Peter J Myler
Journal:  BMC Bioinformatics       Date:  2012-12-02       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.